Literature DB >> 7705218

Hepatic disorders. Features and appropriate management.

M A Aldersley1, J G O'Grady.   

Abstract

The spectrum of liver disease is extremely wide, with many of the underlying disorders having acute and chronic presentations. Most of the underlying pathogenetic mechanisms are accounted for by autoimmune disease, viral infection and toxic insult. The management strategy of any liver disease is a combination of treating the symptoms and complications that arise, as well as drug therapies relevant to the specific underlying diagnosis. Encephalopathy, ascites, spontaneous bacterial peritonitis, variceal bleeding and pruritus are the main complications at which drug therapy is directed, although in some cases it represents only 1 aspect of the overall management. Drug therapy per se is largely ineffective in acute liver failure with the possible exception of acetylcysteine, but many drugs are used in the management of the constituent components of this complex medical emergency. Treatments for specific liver conditions are expanding, especially in the areas of autoimmune and viral disease. The increasing availability and success of liver transplantation has tended to change the emphasis of management, and it is often not appropriate to exhaust the treatment options before referring the patient for transplantation. A comprehensive review of all liver disease is beyond the scope of this article, but hopefully the important principles of management and commonly occurring clinical decisions are discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7705218     DOI: 10.2165/00003495-199549010-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  141 in total

1.  Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial.

Authors: 
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

2.  Failure of insulin and glucagon infusion to stimulate liver regeneration in fulminant hepatic failure.

Authors:  P M Harrison; R D Hughes; A Forbes; B Portmann; G J Alexander; R Williams
Journal:  J Hepatol       Date:  1990-05       Impact factor: 25.083

3.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

4.  Acute hepatic failure--in special relation to treatment.

Authors:  Y Takahashi
Journal:  Jpn J Med       Date:  1983-04

5.  Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.

Authors:  A Crosignani; P M Battezzati; K D Setchell; M Camisasca; E Bertolini; A Roda; M Zuin; M Podda
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

Review 6.  Refractory ascites.

Authors:  B A Runyon
Journal:  Semin Liver Dis       Date:  1993-11       Impact factor: 6.115

7.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

8.  Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study.

Authors:  E Fassio; R Terg; G Landeira; R Abecasis; M Salemne; A Podesta; P Rodriguez; D Levi; D Kravetz
Journal:  J Hepatol       Date:  1992-03       Impact factor: 25.083

9.  Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.

Authors:  R E Poupon; K Ouguerram; Y Chrétien; C Verneau; E Eschwège; T Magot; R Poupon
Journal:  Hepatology       Date:  1993-04       Impact factor: 17.425

10.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

View more
  2 in total

Review 1.  Liver cirrhosis.

Authors:  E J Williams; J P Iredale
Journal:  Postgrad Med J       Date:  1998-04       Impact factor: 2.401

2.  Commentary.

Authors:  Arzu Coban
Journal:  J Neurosci Rural Pract       Date:  2013-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.